Latest Biotech News

AirNexis Therapeutics closed a $200 million series A and secured exclusive rights outside China to HSK39004 (AN01), a PDE3/4 inhibitor for COPD from Haisco Pharmaceutical Group. The deal includes...

The Biotechnology Innovation Organization (BIO) launched the BIO Investment Council (BIC) to improve capital access for emerging biotech companies and to advise on policies that affect early‑stage...

Aktis Oncology raised $318 million in an upsized initial public offering on Jan. 9, 2026, selling 17.65 million shares at $18 apiece. The Boston-based developer, backed by prior private financings...

Palo Alto-based AirNexis Therapeutics closed a $200 million Series A and acquired rights to Haisco’s inhaled PDE3/4 candidate HSK39004 (AN01) outside China, paying $40 million upfront and giving...

Boltz PBC launched out of MIT CSAIL with a $28 million seed round led by Amplify, a16z and Zetta to commercialize an open-science AI stack for molecular structure prediction and therapeutic...

Illumina named former NHGRI director Eric Green chief medical officer, effective Feb. 2, 2026. Green, who led the National Human Genome Research Institute for 16 years, joins Illumina to steer the...

The Biotechnology Innovation Organization (BIO) launched the BIO Investment Council to deepen engagement between venture investors and emerging biotech companies. Chaired by Doug Dieter with...

Financial Times reporting indicates Merck is in preliminary talks to acquire Revolution Medicines for roughly $28–32 billion, a move that would bolster access to Revolution’s late‑stage...

Eikon Therapeutics filed for a U.S. IPO, positioning the structural biology and drug‑discovery company as an early test of public appetite for biotech in 2026. The filing follows a period of...

Alveus Therapeutics emerged with $160 million in financing to advance a Phase 2‑ready lead program that targets the same dual pathway as Amgen’s MariTide, alongside additional candidates including...

Aragen Biologics launched CHOMax, an integrated CHO cell‑line development and early manufacturing platform designed to move antibody programs from DNA to IND‑enabling supply. The company says...

Cellares signed a collaboration with City of Hope to evaluate its Cell Shuttle manufacturing platform and Cell Q quality‑control automation for City of Hope’s CARpool program targeting...

Aktis Oncology completed its initial public offering, pricing 17.65 million shares at $18 each and raising approximately $318 million in gross proceeds. The upsized offering positions the...

Illumina announced the appointment of Eric Green, former director of the National Human Genome Research Institute, as chief medical officer effective February 2. Green will lead Illumina’s...

Major media reported that Merck & Co. has entered talks to acquire Revolution Medicines in a deal valued between $28 billion and $32 billion. The discussions center on Revolution’s oncology...

Eli Lilly announced a definitive agreement to acquire Ventyx Biosciences for $1.2 billion in cash. Lilly said the deal supplements its inflammation portfolio with Ventyx’s NLRP3 inhibitor assets,...

Scientists behind the ‘Baby KJ’ bespoke CRISPR treatment have launched Aurora Therapeutics with seed backing to develop personalized gene‑editing medicines for ultra‑rare mutations. Menlo Ventures...

Alveus Therapeutics closed a $160 million financing to advance its lead obesity program into Phase 2. The company’s primary candidate targets the same receptor combination as Amgen’s MariTide but...

Venture activity surged as private biotech companies secured roughly $2 billion in a concentrated fundraising week ahead of major industry conferences. Multiple startups closed megaround...

Cellares signed an agreement with City of Hope to evaluate the Cell Shuttle automated manufacturing platform and Cell Q quality control system for City of Hope’s CARpool program — an...